Stomach Cancer Market
Stomach Cancer Market : Information by Therapy (Chemotherapy, Surgery),End-User (Hospitals & Clinics, Cancer Research and Treatment Centers, and Diagnostic Centers)—Forecast Till 2026
Market Overview
Stomach cancer, also known as gastric cancer, is the third leading cause for cancer-related deaths across the globe. Several genetic, infectious, environmental, and immunologic factors are known to cause stomach cancer. With the increasing prevalence of gastric cancer, it has become crucial for FDA to approve the launch of new and orphan drugs in the market. In August 2018, Alteogen Inc, a South Korean biotechnology company, received FDA approval for orphan drug designation for antibody-drug conjugate (ALT-P7) that would strengthen the cancer treatment further.
Stomach cancer is fifth most commonly diagnosed, and seventh-most prevalent cancer in the world. In 2017, around 1 million cases of gastric cancers were reported by World Health Organization. Helicobacter pylori infection is a strong risk factor for gastric cancer. According to WHO, around 63% of the stomach cancer deaths are caused by Helicobacter pylori infection. Also, Asia Pacific has the highest number of new cases i.e. 769,728 (74.5%), followed by Europe 133,133 (12.9%), Latin America, and the Caribbean 67,058 (6.5%). According to NIH, in the U.S. alone, 113,054 people had gastric cancer in 2017.
Global stomach cancer market is estimated to reach USD 6.5 billion by 2026 at a CAGR of 5.7% during the forecast period 2019–2026.
Market Snapshot
Market Dynamics
- Cancer research and treatment centers
- Hospitals
- Specialty Clinics
- Research and Development centers
Segmental Analysis
Global stomach cancer market is segmented by therapy, end-users, and regions.
By therapy, the stomach cancer market is segmented into targeted drug therapy, chemotherapy, and surgery.
Chemotherapy is one of the most popular and the second largest treatment used for treating stomach cancer. It is used along with monotherapy, combination therapy, and radiation therapy. 5-FU (fluorouracil), cisplatin, epirubicin, and oxaliplatin are some of the commonly used drugs in chemotherapy. In February 2019, US FDA has approved trifluridine/tipiracil (Lonsurf) for stomach cancer treatment. According to the survey conducted by WHO, around 5 out of every 10 neuroendocrine tumors starts in the stomach and is responsible for 783,000 deaths. According to the National Cancer Institute, the age-adjusted incidence of carcinoid tumors across the globe is approximately 2 per 100,000 persons with the average age of diagnosis 61.4 years. Additionally, carcinoid tumors represent about 0.5% of all newly diagnosed malignancies.
On the basis of end-users, the stomach cancer market is segmented into hospital and specialty clinics, cancer research & treatment centers, and others. Cancer research and treatment center is growing at the fastest CAGR following heavy investments in stomach cancer research and development, rising health expenditure, and increasing ongoing clinical trials for different drugs. As per National Cancer Institute, spending cost on stomach cancer was valued at USD 13.3 million in 2016 which increased to USD 13.4 million in 2017.
Regional Analysis
Geographically, the stomach cancer market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (LAMEA).
Availability of advanced technologies, a growing number of specialty clinics and hospitals for cancer treatment, and increasing cases of stomach cancer are driving the North America stomach cancer market growth. According to the International Agency for Research on Cancer, in 2018, 29,275 new cases of stomach cancer were diagnosed and 13403 people have died of stomach cancer. In Canada alone, 3500 people were diagnosed with stomach cancer, out of which 2100 died from stomach cancer in 2017, Canadian Cancer Society.
The Middle East and Africa regions have the least occurrence of stomach cancer. However, the prevalence is relatively high in Oman and the UAE.
Top Key Players of Stomach Cancer Market
- Merck & Co. Inc.(U.S)
- GlaxoSmithKline plc.(U.K)
- CareFusion(U.S)
- Apotex Inc.(Canada)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited.(Japan)
- Pfizer Inc.(U.S)
- Eli Lilly and Company(U.S)
- Dr. Reddy’s Laboratories Ltd(India)
Report Scope
| Report Metric | Details |
|---|---|
| CAGR | 5.7% |
| Forecast Period | 2023-2031 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
| Segments Covered |
|
| Geographies Covered |
|
Recent Developments
- Historical inferences, findings & analysis of the market from 2019 to 2026
- Projections and performance forecast analysis for the future from 2019 to 2026
- Production and consumption point of view (POV) analysis
- Market drivers, restraint and opportunity analysis, to define market dynamics covering industry, regulatory, innovation, technological & pricing trends
- Comprehensive competitive landscape mapping with recent development covering market leadership, competency, sustainability, and prospects.
Stomach Cancer Market Segmentation
By Therapy
- Targeted drug therapy
- Chemotherapy
- Surgery
By End User
- Hospitals & clinics
- Specialty clinics
- Ambulatory Services
By Region
America
o North America
U.S.
Canada
Mexico
o South America
Europe
o Western Europe
Germany
France
U.K
Italy
Spain
Rest of Western Europe
o Eastern Europe
Asia Pacific
o China
o India
o Japan
o South Korea
o Australia
o Rest of Asia Pacific
The Middle East & Africa
Frequently Asked Questions (FAQs)
USD 995
Purchase Benefits
- Eligible for a free updated report next year
- Completely customizable scope
- 30% discount on your next purchase
- Dedicated account manager
- Query resolution within 24 hours
- Permission to print the report
Report Benefits
- Develop business strategies by understanding the trends shaping and driving the Market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track sales in the global and country-specific Market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
